| Ytd | -38.73% | |
| 1y | -67.52% |
| Open | 6.69 | Prev Close | 6.56 | Low | 6.53 | High | 6.76 | Mkt Cap | 45.71M |
| Vol | 37.62K | Avg Vol | 12.54K | EPS | -4.51 | P/E | N/A | Forward P/E | -1.80 |
| Beta | 1.74 | Short Ratio | 2.29 | Inst. Own | 80.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-04 | 50-d Avg | 7.34 | 200-d Avg | 7.95 | 1yr Est | 100.33 |
TIL News
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical compa
Iovance Biotherapeutics NASDAQ: IOVA said it is expanding its tumor-infiltrating lymphocyte, or TIL,
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.45) per share which missed the analyst cons
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical compa
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculati
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN C
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.97) per share which beat the analyst consen
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of stra
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that i
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licens
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.75) per share which beat the analyst consen
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDiffe
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and
JMP Securities analyst Reni Benjamin reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Ma
HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and
Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Shanghai) I
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.32) per share which beat the analyst consen
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.82) per share which beat the analyst consen
JMP Securities analyst Chris Muller reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Mar
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of